

[Back to Overview \(https://my.ean.org/s/abstracts\)](https://my.ean.org/s/abstracts)**Abstract**
A-21-01000

Edit Abstract

Submit

Withdraw

**Information**

Event

[Congress 2021 \(/s/event/a1M3Y000006Di2EUAS/congress-2021\)](#)

Stage

Submitted

Type

Oral

Status

Pending

Abstract Topic

MS and related disorders

Date Submitted

13.01.2021 17:39

Body

Title

A Patient-based Digital Tool to Detect Early Signs of Changes in MS Symptoms and Progression: Your MS Questionnaire

Introduction

While evaluating MSProDiscuss™, development of a patient-completed tool was a common recommendation to monitor experiences of people with multiple sclerosis (pwMS) over time and facilitate discussions with health-care professionals (HCPs). Your MS Questionnaire (YourMSQ) was developed to be completed by pwMS. Here we evaluate its usability to help both pwMS and HCPs understand changes in MS-symptoms, disease progression, and their impact on daily activities.

Methods

YourMSQ is derived from MSProDiscuss, using input from pwMS, patient organizations and HCPs to include feedback from a broad-range of RRMS/SPMS patients. Asking 15 questions, it captures the perception of pwMS regarding changes in MS-symptoms, disability progression and impact on daily-living over past 6-months. To assess YourMSQ, two surveys (15 questions each) are being conducted among treating neurologists initially after every consultation to understand patient-details, patient-satisfaction, HCP-satisfaction, and again after up to 40 consultations (minimum 10 consultations required). This will capture in-depth feedback on usefulness, integration in clinical practice in addition to MSProDiscuss, and improvement areas. PwMS were given the choice of an electronic or paper version of the questionnaire.

Results

Testing of YourMSQ is currently ongoing across eight countries (US, UK, Germany, Spain, Italy, Canada, Australia and China), permitting assessment of different aspects of its usability. Results will be presented at the meeting.

Conclusion

YourMSQ will collect real-world feedback from pwMS and help neurologists manage MS-disease activity and symptoms in daily-life. When completed before consultations, it may benefit pwMS and physicians through (1) a better-structured conversation and (2) potential use in telemedicine.

Disclosure

The study was supported by Novartis Pharma AG, Switzerland

Author Details

- **Presenter:** Tjalf Ziemssen, Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany
- Enrique Alvarez, University of Colorado School of Medicine, Aurora, CO, United States
- Virender Bhan, University of British Columbia, Vancouver, BC, Canada
- Jason Burton, Centre for Neuromuscular and Neurological Disorders, Western Australian Neuroscience Research Institute, The University of Western Australia, Perth, Australia
- Olaf Hoffmann, Department of Neurology, Alexianer St. Josefs Hospital, Potsdam, Germany
- Celia Oreja-Guevara, Department of Neurology, University Hospital San Carlos, Idissc, Madrid, Spain
- René Robles-Cedeño, Neuroimmunology and Multiple Sclerosis Unit, Girona, Spain
- Maria Trojano, University of Bari, Bari, Italy
- Patrick Vermersch, Univ. Lille, Inserm UMR U1172 LiNCog, CHU Lille, FHU Imminent, Lille, France
- Salvatore Napoli, Partners, Multiple Sclerosis Center, and Center for Neurological Imaging, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
- Augusto Miravalle, Department of Neurology, University of Colorado, Denver, CO, United States

- Yan Xu, Multiple Sclerosis Center, Department of Neurology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
 - Jo Vandercappellen, Novartis Pharma AG, Basel, Switzerland
 - Mudeer Khwaja, Novartis Pharma AG, Basel, Switzerland
 - Mark Marchaterre, Novartis Services Inc., East Hanover, NJ, United States
 - Bianca Stadler, Novartis Pharma GmbH, Nürnberg, Germany
 - Thomas Hach, Novartis Pharma AG, Basel, Switzerland
 - Gavin Giovannoni, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
-